OCLN and hematocrit: Our previous animal study reported that blood occludin level was well-correlated with the extent of BBB damage after ischemic stroke (Pan et al., 2017), and thus serum occludin may serve as a relevant biomarker for assessing the risk of HT before reperfusion therapy (Li et al., 2018).